A 65-year old man on treatment for ischaemic heart disease presented with a history of pain and weakness of all four limbs and dry mouth. He had clinical and neurophysiological features of Lambert-Eaton myasthenic syndrome. His symptoms improved after withdrawal of diltiazem, although neurophysiological changes remained even after 3 months.
Neurophysiology
The needle EMG was normal. Stimulation of the right median nerve yielded a compound muscle action potential (CMAP) with small amplitude, which increased by > 200% after isometric stimulation (post-exercise Exacerbation of symptoms due to diltiazem in a patient with LambertEaton myasthenic myopathic syndrome KD Pathirana 1 and MDP Hidelaratchi 2 (Index words: Calcium channel blockers, diltiazem, Lambert-Eaton myasthenic syndrome) facilitation) and reduced to 21% after rest ( Figure 1 ). Repetitive stimulation of the median nerve at 3 Hz did not show a significant change; at 20 Hz a decrement was shown while at 50 Hz a more than 300% increment response was seen ( Figure 2 ). These finding were compatible with Lambert-Eaton myastheric syndrome (LEMS). On admission, lovastatin was stopped considering the possibility of statin induced myositis. Due to lack of improvement in symptoms after its withdrawal and normal CPK, lovastatin was reintroduced.
Diltiazem was stopped after confirmation of LEMS and the patient was reassessed after 3 months. At this stage he had partial improvement of the symptoms, though the neurophysiological studies revealed the same changes. He was then treated with pyridostigmine as 2, 4 -diaminopyridine was not available. He was free of symptoms without any drugs 6 months after withdrawing diltiazem. As he did not consent for further neurophysiological tests, a continuous follow up and periodic reassessment to screen for any underlying malignancy is planned.
Discussion
Lambert-Eaton myasthenic syndrome is an uncommon disorder of the neuromuscular junction, caused by antibodies against voltage-gated calcium channels (VGCC) of the presynaptic nerve endings. It can be broadly divided into two groups-those associated with malignancy and those without association. The commonly encountered carcinoma is the small cell carcinoma of the lung (SCLC) which accounts to about 60% of the cases, while lymphoproliferative disorders, carcinoma of the breast, colon, pancreas, prostate are rare associations [1] . In a patient presenting with LEMS the probability of having a SCLC falls significantly after 2 years, while it is almost negligible after 4-5 years [2] . This category is considered to be the idiopathic group.
The classical presentation of LEMS is with proximal myopathy and autonomic symptoms such as dry mouth, impotence and bladder or bowel symptoms. LEMS associated with carcinoma presents at a later age (mean 57.9 years), while those without, present relatively early (mean 48 years). In both groups a male preponderance is seen [3] .
The release of neurotransmitters at the presynaptic motor nerve terminals of the neuromuscular junction and autonomic neurons depends on the influx of calcium through the VGCC. Over 90% of patients in both groups of LEMS have antibodies against P/Q type VGCCs [4, 5] , though it has a stronger bearing to carcinoma associated LEMS.
Calcium channel blockers are known to interact with VGCCs in vitro [6] . After an extensive search in literature we found only a few reports of calcium channel blockers precipitating symptoms of neuromuscular junction disorders. Felodipine, nifedipine and verapamil exacerbating symptoms of myasthenia gravis and possible LEMS have been previously reported [7] . Ueno and Hara have reported a 59-year old man with IHD who had developed clinical and electromyographic changes of LEMS following treatment with diltiazem which improved clinically and neurophysiologically after withdrawal of the drug [8] .
Our patient fulfills the neurophysiological criteria to confirm the diagnosis of LEMS. Improvement of symptoms but not neurophysiological features probably indicates that this is a case of LEMS exacerbated by diltiazem, rather than LEMS caused by diltiazem, as proposed by Ueno and Hara. Hence there is a need for follow up of this patient for an underlying malignancy at least for 5 years to detect the same.
